Unknown

Dataset Information

0

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).


ABSTRACT: New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ?3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical activity endpoint) were, 7.1 (SD 2.3, placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial of mirtazapine is indicated. Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-11).

SUBMITTER: Higginson IJ 

PROVIDER: S-EPMC7029228 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).

Higginson Irene J IJ   Wilcock Andrew A   Johnson Miriam J MJ   Bajwah Sabrina S   Lovell Natasha N   Yi Deokhee D   Hart Simon P SP   Crosby Vincent V   Poad Heather H   Currow David D   Best Emma E   Brown Sarah S  

Thorax 20200108 2


New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or  ...[more]

Similar Datasets

| S-EPMC7689088 | biostudies-literature
| S-EPMC10562841 | biostudies-literature
| S-EPMC9832733 | biostudies-literature
| S-EPMC9026613 | biostudies-literature
| S-EPMC5726102 | biostudies-literature
| S-EPMC4414812 | biostudies-literature
| S-EPMC6882005 | biostudies-literature
| S-EPMC4930675 | biostudies-literature
| S-EPMC6598548 | biostudies-literature
| S-EPMC8546216 | biostudies-literature